Spotlight Innovation, Inc.

ORLANDO, Fla., June 22, 2024 /PRNewswire/ -- Today, the American Diabetes Association ® (ADA) announced the winners of its Innovation Challenge competition. Innovators showcased novel ideas for diabetes care before a panel of potential funders and an audience of professionals in the field, with the goal of furthering transformative solutions for people living with diabetes, their families, and caregivers. Five finalists pitched ideas from the main stage at the ADA's 84th Scientific Sessions and three winners were chosen— Diatech Diabetes, Spotlight Communications, and Symbio Cell Tech. The competition comes amidst a diabetes epidemic affecting over 38 million Americans. Increased efforts to bend the curve of diabetes, coupled with advancements in technology and scientific understanding have created a growing market for diabetes startups. "The potentially game-changing ideas presented by these innovators bring the ADA's vision of a life free of diabetes and all its burdens closer to reality. We're proud to support emerging advancements in diabetes research and care," said Robert Gabbay, chief scientific and medical officer of the ADA. "Our congratulations to the winners, with appreciation for their hard work and excitement for what's to come." This year's winners and finalists included: Winner: Diatech Diabetes – A software platform to improve infusion failure detection in insulin pump and automated insulin deliver (AID) systems. The mobile app integrates with insulin pumps allowing people with diabetes to monitor their infusions and avoid hyperglycemia. Winner: Spotlight Communications – A clinical tool to address patient-identified priority concerns and immediately map resources to meet unmet physical, mental and social wellbeing needs. Winner: Symbio Cell Tech – A biotherapy for patients with type 1 diabetes that does not require encapsulation devices or antirejection drugs. Finalist: Spect – A smartphone-enabled telemedicine platform for eye screening that trains medical assistants and returns a diagnostic report in minutes. Finalist: Valendo Health – Delivery of a program to address the shortage of endocrinologists, beginning with increasing clinical capacity and enhancing patient care by delivering telehealth and remote patient monitoring services. The application period for next year's Innovation Challenge will open in January 2025. About the American Diabetes Association's Scientific Sessions The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life®. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn). Media Contact: Amy Robinson [email protected] SOURCE American Diabetes Association

Dr. Pierre Kory to transition from operational role to co-founder and president emeritus WASHINGTON, May 9, 2024 /PRNewswire/ -- The FLCCC Alliance announced today that Dr. Joseph Varon, one of the original co-founders of the organization, has been named president and chief medical officer; he has also been appointed to the board of directors. A globally recognized front line physician and highly published scientist, Dr. Varon is fluent in seven languages and is also the founder of multiple businesses, possessing outstanding organizational leadership skills that the FLCCC requires to execute the strategic plan formulated last fall to significantly expand its breadth of focus, reach, and global impact. Three other founding FLCCC physicians/scientists have also stepped into expanded leadership roles pursuant to the strategic plan. Dr. Umberto Meduri, the world's leading expert in corticosteroid treatment of acute respiratory distress syndrome (ARDS) and severe pneumonia, has been appointed senior fellow medical and research integrity; Dr. Fred Wagshul, a leading Ohio-based pulmonologist who developed revolutionary treatments for asthma, has been appointed senior fellow pulmonary medicine; Dr. Jose Iglesias, medical director of the John J. DePalma Renal Institute of Central Jersey and a specialist in hypertension, critical care, and septic shock medicine, has been appointed senior fellow nephrology. Dr. Pierre Kory is finalizing the transition of his responsibilities to Dr. Varon over the next 45 days. With the full encouragement and support of the FLCCC Alliance, Dr. Kory is shifting his primary focus to his rapidly growing private practice, Leading Edge Clinic, which is focused on the care of a growing number of patients suffering from vaccine-related injuries. In addition, he plans to devote more time to writing for his Substack blog at pierrekorymedicalmusing.com while also continuing his efforts as a powerful spokesman through his international advocacy work. "I have immense gratitude for Pierre's dedication to the FLCCC. We could not be where we are today without him," said Dr. Paul Marik, co-founder and chief scientific officer. "I wish Pierre well as he focuses more on his patients and am glad that he and I will still work together on vaccine injury and cancer treatment." "The FLCCC became something far beyond what we could have imagined just four years ago, and I couldn't be prouder of what we accomplished," said Dr. Kory. "I am excited to focus more on my practice and look forward to a continued collaboration on the FLCCC observational cancer study." The FLCCC's strategic growth plan process began over six months ago, initiated by the formation of an executive committee comprised of three of the FLCCC's five independent directors — who possess significant entrepreneurial and public company organizational leadership experience. This committee will continue to work in collaboration with the FLCCC's management team and staff, including Dr. Varon, to execute its new strategic plan. The organization recently initiated the public unveiling phase of the plan at the FLCCC's annual conference in Phoenix, Arizona, in February 2024 with its new "Honest Medicine" mission that seeks to restore trust, integrity, and the doctor-patient relationship to the medical system. "Ours is the very rare exception — where an early-stage and high-growth organization can effectively make the successful transition from the 'start-up' to the 'leadership-expansion and growth' phase without having to look outside of the organization to harness the talent that is required to do so," said Dr. Varon. "Our board and management team could not be more excited about our strategic plan and the seamless execution of its first phase." "We've appointed Dr. Varon to this core executive leadership role while simultaneously deepening the bench under him, with original founding FLCCC physicians in whom we have supreme confidence, to elevate our growth and execute our important mission to restore trust and integrity in medicine and protect the sacrosanct doctor-patient relationship," said Kelly Bumann, executive director of the FLCCC Alliance. "And with the continued generosity of our supporters, the best is yet to come as we accelerate the FLCCC's core mission to deliver 'Honest Medicine' globally." About the FLCCC Alliance The FLCCC Alliance was organized in March 2020 by a group of highly published, world renowned critical care physicians and scholars with the academic support of allied physicians worldwide. Known for its lifesaving protocols for preventing and treating COVID-19 in all stages of illness including "long COVID" and post-vaccination syndrome, the FLCCC has since broadened its scope with the development of various treatment guides for several conditions and illnesses, including sepsis, metabolic disease, cancer, and depression. The organization's larger mission is one driven by Honest MedicineTM and puts patients above profits and emphasizes long-term wellness via the prevention of disease and the empowerment of physicians and their patients. For more information visit flccc.net. Media Contact: Damon Elder Spotlight Marketing Communications (949) 427-1377 [email protected] SOURCE FLCCC Alliance

SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced its exclusively licensed induced pluripotent stem call (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA). "We're thrilled to strengthen our existing suite of patents," said Peter Choo, Chairman of CytoMed. "Now this novel iPSC-based technology has been granted patent in China and Japan (where the iPSC technology was pioneered in 2006). Such progress further expands the Company's current patent portfolio to three countries, consisting of and including patents granted in the US and China for our licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology which is expected to start phase I clinical trial in Singapore soon." The granted patent is titled "Methods and Kits for Generating Mimetic Innate Immune Cells from Pluripotent Stem Cells" under Patent No. ZL201880022790.X, published as CN 110691844 B. CytoMed's new patent specifically covers tech to derive novel synthetic γδ NKT cells for the treatment of a wide range of cancers, such as hematological malignancies and solid tumors. Immune cells like γδ NKT cells and natural killer (NK) cells are extremely valuable as a viable cancer treatment due to their ability to express an array of built-in receptors that can naturally recognize stress-induced cancer antigens. Using the patented iPSC technology, CytoMed can generate novel types of synthetic hybrid immune cells, γδ NKT cells, which can express receptors of both γδ T cells and NK cells without the use of genetic modification or viral vectors. As a result, the company can use this as an allogeneic cell source to become a potential "off-the-shelf" cell therapy capable of helping a large number of cancer patients. The assets continue its preclinical development and CytoMed maintains an exclusive, worldwide license to use this patented technology as stated under its previously disclosed licensing agreement from June 1, 2018. For more information about the company's services, latest news, and ongoing initiatives, visit and About CytoMed Therapeutics Limited Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology, and Research (A*STAR), Singapore's national research and development agency in the public sector. CytoMed is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. For more information about CytoMed, please visit . About Spotlight Growth SpotlightGrowth.com is a digital hub for micro-caps, small-caps, venture capital, private equity, crowdfunding, cryptocurrency, and other emerging growth investors. SpotlightGrowth.com serves as our media subsidiary and provides insights on small-cap companies. Follow us on social media: Twitter; Facebook; Instagram; Reddit; and YouTube. Disclaimer This communication was produced by Spotlight Growth (SG), an IR advisor to small and micro-cap companies. SG is not a registered or licensed broker-dealer or investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. SG may be compensated by respective clients for publicizing information relating to its client's securities. See for more information. Contact: CytoMed Therapeutics enquiry@cytomed.sg Spotlight Growth info@spotlightgrowth.com SOURCE: CytoMed Therapeutics Limited View source version on accesswire.com: